<p>Cencora（COR）于 2025 年 12 月 22 日发生了新的内部交易活动。</p>
<h3>享受 TipRanks 高级会员 50% 的折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Cencora 最近出现了显著的内部出售活动，三位高管近期兑现了大量持股。总裁兼首席执行官 Robert Mauch 出售了 5,096 股 Cencora 股票，交易价值为 1,750,221 美元。执行副总裁 Elizabeth S. Campbell 处置了 3,351 股，总计 1,146,377 美元。此外，执行副总裁 Silvana Battaglia 出售了 1,677 股，获得 578,565 美元的收益。这些销售共同突显了 Cencora 领导团队的显著获利了结。</p>
<p><strong>COR 股票的最新动态</strong></p>
<p>在过去 24 小时内，Cencora 的股票走势主要受到指导和分析师评论的驱动，而非任何单一的价格冲击。公司重申了 2026 财年的收入增长前景为 5%-7%，显示出对持续运营执行的信心，但指出当前年度的调整后每股收益可能会落在指导范围的下限，因为公司暂停了股票回购，以优先考虑计划收购 OneOncology——这种短期每股收益支持与长期战略增长之间的权衡是分析师重新评估的关键因素。巴克莱在对美国医疗技术和分销领域的整体中性观点下，对 Cencora 进行了积极的覆盖，指出相对于对牙科和医疗 IT 公司的较为复杂的情绪，药品分销商的前景特别乐观，这支撑了其对该股票的建设性定位。同时，新披露的风险因素评论强调了 Cencora 面临的全球事件（如公共卫生危机、自然灾害和地缘政治紧张局势）带来的干扰风险，提醒投资者尽管公司有强劲的增长前景和整体支持的华尔街情绪，供应链和运营波动可能会对业绩产生实质性压力。</p>
<p><strong>Spark 对 COR 股票的看法</strong></p>
<p>根据 Spark，TipRanks 的 AI 分析师，COR 的评级为中性。</p>
<p>Cencora 强劲的财务表现和积极的财报电话会议情绪是主要优势，推动了评分。然而，高杠杆、潜在的高估值以及技术指标显示的看跌动能是显著风险。</p>
<p>要查看 Spark 关于 COR 股票的完整报告，请点击这里。</p>
<p><strong>关于 Cencora 的更多信息</strong></p>
<p><strong>年初至今价格表现：</strong> 52.91%</p>
<p><strong>平均交易量：</strong> 1,485,270</p>
<p><strong>技术情绪信号：</strong> 买入</p>
<p><strong>当前市值：</strong> 661.4 亿美元</p>

<p>Cencora 高管已出售大量股份，首席执行官 Robert Mauch 出售了价值 175 万美元的股份。该公司重申了其 2026 财年的收入增长前景，但由于暂停股票回购以进行收购，预计每股收益将下降。巴克莱对 Cencora 持积极看法，尽管医疗保健行业情绪不一。风险包括全球干扰影响供应链。Spark 将 COR 股票评级为中性，指出其财务状况良好，但杠杆率高且可能被高估</p>

<p>New insider activity at Cencora ( (COR) ) has taken place on December 22, 2025.</p>
<div class="lb-trans"><p>Cencora（COR）于 2025 年 12 月 22 日发生了新的内部交易活动。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>享受 TipRanks 高级会员 50% 的折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Cencora has seen notable insider selling activity, with three top executives recently cashing out significant holdings. President &amp; CEO Robert Mauch sold 5,096 shares of Cencora stock in a transaction valued at $1,750,221. Executive Vice President Elizabeth S. Campbell disposed of 3,351 shares for a total of $1,146,377. Additionally, Executive Vice President Silvana Battaglia sold 1,677 shares, generating proceeds of $578,565. These sales together highlight substantial profit-taking by Cencora’s leadership team.</p>
<div class="lb-trans"><p>Cencora 最近出现了显著的内部出售活动，三位高管近期兑现了大量持股。总裁兼首席执行官 Robert Mauch 出售了 5,096 股 Cencora 股票，交易价值为 1,750,221 美元。执行副总裁 Elizabeth S. Campbell 处置了 3,351 股，总计 1,146,377 美元。此外，执行副总裁 Silvana Battaglia 出售了 1,677 股，获得 578,565 美元的收益。这些销售共同突显了 Cencora 领导团队的显著获利了结。</p>
</div><p><strong>Recent Updates on COR stock</strong></p>
<div class="lb-trans"><p><strong>COR 股票的最新动态</strong></p>
</div><p>In the last 24 hours, Cencora’s stock action has been driven mainly by guidance and analyst commentary rather than any single price shock. The company reaffirmed its fiscal 2026 revenue growth outlook of 5%–7%, signaling confidence in continued operational execution, but noted that its adjusted EPS for the current year is likely to land toward the lower end of its guidance range because it is pausing share repurchases to prioritize the planned acquisition of OneOncology—this trade-off between near-term EPS support and long-term strategic growth is a key factor behind analysts’ reassessments. Barclays initiated coverage with a positive stance on Cencora within a broadly neutral view of the U.S. healthcare technology and distribution space, citing a particularly favorable outlook on drug distributors relative to more mixed sentiment on dental and healthcare IT names, which underpins its constructive positioning on the stock. At the same time, newly disclosed risk-factor commentary emphasized Cencora’s exposure to disruptions from global events such as public health crises, natural disasters, and geopolitical tensions, reminding investors that supply-chain and operational volatility could materially pressure performance despite the company’s strong growth outlook and supportive Wall Street sentiment overall.</p>
<div class="lb-trans"><p>在过去 24 小时内，Cencora 的股票走势主要受到指导和分析师评论的驱动，而非任何单一的价格冲击。公司重申了 2026 财年的收入增长前景为 5%-7%，显示出对持续运营执行的信心，但指出当前年度的调整后每股收益可能会落在指导范围的下限，因为公司暂停了股票回购，以优先考虑计划收购 OneOncology——这种短期每股收益支持与长期战略增长之间的权衡是分析师重新评估的关键因素。巴克莱在对美国医疗技术和分销领域的整体中性观点下，对 Cencora 进行了积极的覆盖，指出相对于对牙科和医疗 IT 公司的较为复杂的情绪，药品分销商的前景特别乐观，这支撑了其对该股票的建设性定位。同时，新披露的风险因素评论强调了 Cencora 面临的全球事件（如公共卫生危机、自然灾害和地缘政治紧张局势）带来的干扰风险，提醒投资者尽管公司有强劲的增长前景和整体支持的华尔街情绪，供应链和运营波动可能会对业绩产生实质性压力。</p>
</div><p><strong>Spark’s Take on COR Stock</strong></p>
<div class="lb-trans"><p><strong>Spark 对 COR 股票的看法</strong></p>
</div><p>According to Spark, TipRanks’ AI Analyst, COR is a Neutral.</p>
<div class="lb-trans"><p>根据 Spark，TipRanks 的 AI 分析师，COR 的评级为中性。</p>
</div><p>Cencora’s strong financial performance and positive earnings call sentiment are major strengths, driving the score. However, high leverage, potential overvaluation, and technical indicators suggesting bearish momentum are notable risks.</p>
<div class="lb-trans"><p>Cencora 强劲的财务表现和积极的财报电话会议情绪是主要优势，推动了评分。然而，高杠杆、潜在的高估值以及技术指标显示的看跌动能是显著风险。</p>
</div><p>To see Spark’s full report on COR stock, click here.</p>
<div class="lb-trans"><p>要查看 Spark 关于 COR 股票的完整报告，请点击这里。</p>
</div><p><strong>More about Cencora</strong></p>
<div class="lb-trans"><p><strong>关于 Cencora 的更多信息</strong></p>
</div><p><strong>YTD Price Performance:</strong> 52.91%</p>
<div class="lb-trans"><p><strong>年初至今价格表现：</strong> 52.91%</p>
</div><p><strong>Average Trading Volume:</strong> 1,485,270</p>
<div class="lb-trans"><p><strong>平均交易量：</strong> 1,485,270</p>
</div><p><strong>Technical Sentiment Signal:</strong> Buy</p>
<div class="lb-trans"><p><strong>技术情绪信号：</strong> 买入</p>
</div><p><strong>Current Market Cap:</strong> $66.14B</p>
<div class="lb-trans"><p><strong>当前市值：</strong> 661.4 亿美元</p>
</div>

Cencora 的高管们在重大内部股票交易中悄然套现